Alvotech & Changchun High & New Technology enter into Joint Venture

Biopharmaceutical company Alvotech and Changchun High & New Technology (CCHN) have entered into a joint venture. Alvotech, headquartered in Iceland, is developing biosimilar monoclonal antibodies and is the sister company of Alvogen – a global leader in developing, manufacturing and selling generic, brand, over-the-counter and biosimilar products.

The joint venture will enable Alvotech and Alvogen to globally expand the development, manufacturing and commercialization of the biosimilar portfolio in China, beginning with a state-of-the-art biologics drug facility.

CCHN is an established leader in China, with in-depth market knowledge and expertise. CCHN will contribute $100-million USD to the venture, with Alvotech contributing capital and six drug-market authorizations, valued at $100-million USD.

Life science companies, such as drug development companies and biopharmaceuticals, incorporated in Iceland benefit from low corporate tax and encouraging financial incentives for the clinical trial R&D and commercial applications. To learn more, please visit Invest in Iceland.

Article image and information from Robert Wessman, Chairman and CEO at Alvogen.


Get in touch

For further information on the benefits of establishing a business in Iceland please feel free to contact us.